Cutaneous Crohn’s disease unmasked during interleukin 17 inhibition for hidradenitis suppurativa: A 2-patient case series

Ysaac Zegeye, Saranya Ravi, Carrie Diamond, Ashley Rose Scholl Loew, Maria Angelica Selim, Anne L Marano, Amber Fresco · 2026

Read Cutaneous Crohn’s disease unmasked during interleukin 17 inhibition for hidradenitis suppurativa: A 2-patient case series by Ysaac Zegeye, Saranya Ravi, Carrie Diamond, Ashley Rose Scholl Loew, Maria Angelica Selim, Anne L Marano, Amber Fresco (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13471224.txt.

Description

Ysaac Zegeye and colleagues report in 2026 two patients whose skin Crohn disease surfaced during treatment for a different chronic skin condition. Both patients had hidradenitis suppurativa. That is a painful, recurring disease of abscesses and tunnels in skin fold areas. Both were receiving a biologic drug that blocks interleukin 17. Such drugs are a standard escalation for stubborn cases.

During that treatment, lesions appeared. The lesions proved to be cutaneous Crohn disease, an uncommon skin expression of the inflammatory bowel condition. The timing raised the question the case series is built around. Can blocking interleukin 17 unmask Crohn disease that was quietly present? That worry already exists for gut inflammation with this drug class. The authors present the pair of cases so clinicians weigh bowel symptoms and skin changes in patients on this therapy.

Catalog record

CREATORYsaac Zegeye, Saranya Ravi, Carrie Diamond, Ashley Rose Scholl Loew, Maria Angelica Selim, Anne L Marano, Amber Fresco
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE10315
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13471224

Browse the full library · About the Tower of Babel